Automatically comply with CDISC standards.

No worries about meeting regulatory standards. ryze is built on the latest CDISC compliant templates, so you automatically comply with the latest FDA and NCI standards. And if you’re importing existing content or legacy studies into ryze, our CDISC validation tools flag up any issues and help you get them fixed!

Validation is built in throughout ryze from the start, so you save time and resource both during and after clinical study build. Now you can submit studies faster, as validation has been done continuously, and not left until submission at the end.

No need to have CDISC or programming expertise. Built in standards and automated processes do all the hard work for you. This saves masses of time and you’ll need fewer resources to conduct your trials.

ryze shows what your source datasets will be, early on. Before you’ve even collected any patient data, you’ll know what your variable column headings are. That means you can get a head start on designing your SDTM datasets. And start your SDTM mappings early too. By the time you get trial data back, your datasets are all mapped, and it’s just 1 click to do your SDTM conversion in ryze.

Because there are no worries about being CDISC compliant, your data will be of better quality. By reusing content, you’ll reduce manual errors. And, if you’re reusing content from your standardized library, it’s already been pre-approved.

You don’t need to be an expert in SAS or have any programming experience. ryze automates a lot of the processes that typically require double coding. Like mapping specifications, metadata specifications, and define.xml. And our easy-to-use mapping tools let you create machine-readable mappings, without any coding.

Build your organizational standards in ryze, and reuse them again and again. Whether it’s forms, edit checks, dataset designs, or mappings… do it once, get it approved. There’s no need to create content from scratch each time.

Share content and work together from anywhere. ryze clinical metadata repository keeps everything in 1 place, allowing teams to work more effectively and efficiently.

ryze is the only platform that lets you design CRFs, create SDTM datasets, reuse content, as well as build studies for leading EDCs, and automate SDTM conversions – all in one cloud suite.

ryze is the only Clinical Metadata Repository that lets you design and visualize eCRFs inside the platform. You can see exactly how eCRFs look, and how they work for leading EDCs – without having to build your EDC and go back and forth between platforms to edit and review.

With ryze, you can build your study in a fraction of the time it normally takes – in as little as 6 weeks! Building studies from standardized content not only speeds up design, but also increases quality and consistency across studies and standards.

ryze is the only platform that supports such a breadth of CDISC, 3^rd party, and in-house metadata. You can design CDISC metadata in any version of SDTM, ADaM, SEND, or NCI Controlled Terminology. Plus, you can design edit checks, EDC specific metadata, 3rd party lab transfer specs, mapping metadata, and analysis results metadata to name a few examples.

With ryze, you can transfer metadata between various platforms – such as EDCs – and continually reuse it. There’s no need to redesign, retype, or retest content if you switch EDCs for example. Just move your assets and reuse them. ryze is the only EDC vendor neutral platform that gives this level of reusability across systems.

ryze is the only commercial off-the-shelf solution that’s available for use immediately, and requires very little ryze can be very quickly tailored to your specific needs, with no long or complex implementation.

ryze is the only solution used by CDISC to design CDASH example CRFs. They create, visualize, edit and approve eCRFs in ryze, then export them in ODM-XML to publish on their CDASH eCRF portal.

You get your first SDTM dataset conversions much faster with ryze – in as little as 4 weeks, or even less! As soon as patient data is live in the EDC, you can see it. So you can act upon trial data far quicker. In fact, our platform was recently used to determine safety and efficacy in several COVID vaccination studies.